Gerald Rosen1, Anne K Harris2, Meixia Liu3, Jill Dreyfus3, James Krueger4, Yoav H Messinger2. 1. Sleep Medicine, Children's Hospitals and Clinics of Minnesota, St. Paul, MN, United States. Electronic address: rosen052@umn.edu. 2. Pediatric Hematology/Oncology, Children's Hospitals and Clinics of Minnesota, Minneapolis, MN, United States. 3. Research & Sponsored Programs, Children's Hospitals and Clinics of Minnesota, Minneapolis, MN, United States. 4. Sleep and Performance Research Center, Washington State University, Spokane, WA, United States.
Abstract
PURPOSE: Corticosteroids, which are a mainstay in the treatment of acute lymphoblastic leukemia (ALL), have a well-documented adverse effect on sleep. We sought to characterize the effects of dexamethasone on sleep over an entire 28-day treatment cycle using actigraphy, an objective measure of sleep. METHODS: The sleep of 25 children aged 2-9 years (mean 4.5 years) with ALL treated with dexamethasone were evaluated during maintenance chemotherapy using a within-subject experimental design, actigraphy, and standardized questionnaires to assess sleep, sleep problems, and fatigue. RESULTS: During the five days of dexamethasone treatment, sleep time increased during the night (535 vs. 498 min; p = 0.004) and daytime napping increased the following day (14 vs. 0 min; p = 0.002), and the number of wake episodes during the night was lower (14 vs. 20; p = ≤ 0.001). However, when assessed individually, sleep-onset time, efficiency, and wake after sleep onset during the night were unchanged during dexamethasone treatment; when the cumulative effect of all of these factors was assessed, there was a statistically and clinically significant increase in nighttime sleep duration during dexamethasone treatment. CONCLUSIONS: During the five days of treatment with dexamethasone, an increase in nighttime sleep as well as daytime napping was observed in young children with ALL. The increases in sleep duration return to baseline one day after the discontinuation of dexamethasone.
PURPOSE: Corticosteroids, which are a mainstay in the treatment of acute lymphoblastic leukemia (ALL), have a well-documented adverse effect on sleep. We sought to characterize the effects of dexamethasone on sleep over an entire 28-day treatment cycle using actigraphy, an objective measure of sleep. METHODS: The sleep of 25 children aged 2-9 years (mean 4.5 years) with ALL treated with dexamethasone were evaluated during maintenance chemotherapy using a within-subject experimental design, actigraphy, and standardized questionnaires to assess sleep, sleep problems, and fatigue. RESULTS: During the five days of dexamethasone treatment, sleep time increased during the night (535 vs. 498 min; p = 0.004) and daytime napping increased the following day (14 vs. 0 min; p = 0.002), and the number of wake episodes during the night was lower (14 vs. 20; p = ≤ 0.001). However, when assessed individually, sleep-onset time, efficiency, and wake after sleep onset during the night were unchanged during dexamethasone treatment; when the cumulative effect of all of these factors was assessed, there was a statistically and clinically significant increase in nighttime sleep duration during dexamethasone treatment. CONCLUSIONS: During the five days of treatment with dexamethasone, an increase in nighttime sleep as well as daytime napping was observed in young children with ALL. The increases in sleep duration return to baseline one day after the discontinuation of dexamethasone.
Authors: Ann M Berger; Amy Pickar Abernethy; Ashley Atkinson; Andrea M Barsevick; William S Breitbart; David Cella; Bernadine Cimprich; Charles Cleeland; Mario A Eisenberger; Carmen P Escalante; Paul B Jacobsen; Phyllis Kaldor; Jennifer A Ligibel; Barbara A Murphy; Tracey O'Connor; William F Pirl; Eve Rodler; Hope S Rugo; Jay Thomas; Lynne I Wagner Journal: J Natl Compr Canc Netw Date: 2010-08 Impact factor: 11.908
Authors: Anna M Larson; Robin C C Ryther; Melanie Jennesson; Alexandra L Geffrey; Patricia L Bruno; Christina J Anagnos; Ali H Shoeb; Ronald L Thibert; Elizabeth A Thiele Journal: Epilepsia Date: 2012-05-17 Impact factor: 5.864
Authors: Kelly Vallance; Wei Liu; Belinda N Mandrell; John C Panetta; Jami S Gattuso; Marilyn Hockenberry; Sue Zupanec; Lei Yang; Jie Yang; Pamela S Hinds Journal: Eur J Cancer Date: 2010-04-17 Impact factor: 9.162
Authors: Renata Meixner; Rebecca Gerhardstein; Ryan Day; C Keith Nykamp; Mary Lou Syron; Leon Rosenthal Journal: Psychophysiology Date: 2003-03 Impact factor: 4.016
Authors: Lauren C Daniel; Yimei Li; Jacqueline D Kloss; Anne F Reilly; Lamia P Barakat Journal: Support Care Cancer Date: 2016-04-23 Impact factor: 3.603
Authors: Shosha H M Peersmann; Annemieke van Straten; Gertjan J L Kaspers; Adriana Thano; Esther van den Bergh; Martha A Grootenhuis; Raphaële R L van Litsenburg Journal: Trials Date: 2021-04-26 Impact factor: 2.279
Authors: Austin L Brown; Kimberly P Raghubar; Olga A Taylor; Melanie Brooke Bernhardt; Lisa S Kahalley; Wei Pan; Philip J Lupo; Marilyn J Hockenberry; Michael E Scheurer Journal: Support Care Cancer Date: 2020-09-14 Impact factor: 3.603
Authors: Lindsay M H Steur; Gertjan J L Kaspers; Eus J W Van Someren; Natasha K A Van Eijkelenburg; Inge M Van der Sluis; Natasja Dors; Cor Van den Bos; Wim J E Tissing; Martha A Grootenhuis; Raphaële R L Van Litsenburg Journal: Sleep Date: 2020-06-15 Impact factor: 5.849
Authors: L M H Steur; G J L Kaspers; E J W van Someren; N K A van Eijkelenburg; I M van der Sluis; N Dors; C van den Bos; W J E Tissing; M A Grootenhuis; R R L van Litsenburg Journal: Support Care Cancer Date: 2020-04-13 Impact factor: 3.603